Baidu
map

全世界只有这两个可称为“神药”

2017-12-11 佚名 赛柏蓝

近日,一年卖出7.5亿的洗脑“神药”莎普爱思被推到风口浪尖。其实,在我们生活中,真的有一些当之无愧的“神药”。

近日,一年卖出7.5亿的洗脑“神药”莎普爱思被推到风口浪尖。其实,在我们生活中,真的有一些当之无愧的“神药”。

阿司匹林

如果世上真的存在神药,那一定是阿司匹林。

阿司匹林,也叫乙酰水杨酸,是一种历史悠久的解热镇痛药,诞生于1899年3月6日。它不同于现在的西药,没有动辄五六百的分子量,没有花里花哨的结构。他只是从杨树皮里面演化而来,享誉盛名,却低调到尘埃里。

它不但用于可用于治疗感冒、发热、头痛、牙痛、关节痛、风湿病,还具有对血小板聚集的抑制作用可谓“一专多能”,因此被很多人称为“万能神药”。然而,阿司匹林的作用,远不止这些。

促进抗癌剂作用:

近日,据生物探索报道,澳大利亚昆士兰大学在Clinical Cancer Research发表的一项新研究表明,在一些现有的抗癌药物中加入阿司匹林,可以增加抗肿瘤治疗的有效性。

文章的作者Helmut Schaider表示:“我们发现将阿司匹林加入癌症抑制剂药物索拉非尼(Sorafenib)后,能在RAS基因突变的肺癌和黑色素瘤小鼠模型中增强其有效性。”

同时研究人员认为添加阿司匹林也有可能防止患者肿瘤复发。阿司匹林与其他抗癌药物的联合研究已经在进行中。

抗癌作用:

来自中新网11月1日信息,据俄罗斯卫星网1日报道,科学家在西班牙巴塞罗那举行的胃肠病学家会议上发言称,不断服用小剂量的阿司匹林,可多次降低肝、胃及大多数与消化与代谢有关的器官的患癌几率。

据做实验的医生介绍,阿司匹林可数倍增加免疫疗法的效率,也能独立对抗白血病、直肠癌和其他肿瘤,并能将化疗后生存的几率提高15-20%。

帮助修复蛀牙:

近日,来自英国女王大学的研究人员通过研究发现,阿司匹林或能有效逆转蛀牙所带来的影响,这或许就能够减少人们补牙的需要。

研究发现,低剂量的阿司匹林或能明显增加牙齿的矿化作用,并且增强形成牙本质的基因的表达,蛀牙通常会破坏牙齿中硬齿的结构,研究者指出,阿司匹林的抗炎性及疼痛减缓效应或许能够题为一种解决方法来帮助控制个体蛀牙引发的神经痛和炎症,同时还能够促进天然的牙齿修复。


提起二甲双胍,可追溯到20世纪20年代,是从一种名为“山羊豆”的植物中提取出来的胍类物质,1957年二甲双胍正式应用于临床。从此,与阿司匹林一同扛下“神药”的大旗。

二甲双胍是一类治疗2型糖尿病的“权威”用药,在国内外多种治疗指南中被列为一线降糖药物。该药物有降糖作用确切,低血糖风险小,价格低廉等优点,是目前应用最为广范的甲类降糖药物之一。

近年来,随着研究的深入,二甲双胍在降糖作用之外,还有许多让人惊喜的发现。

抗衰老作用:

目前,美国食品和药物管理局是批准了“用二甲双胍对抗衰老”的临床试验,国外科学家之所以将二甲双胍作为抗衰老候选药物,可能是因为二甲双胍能增加向细胞中释放的氧分子数量,从道理上来说,这似乎能增加机体的强健程度并延长寿命。

减肥作用:

二甲双胍是一种能减肥的降糖药。其能增加胰岛素的敏感性,减少脂肪的合成。而对于很多2型糖友而言,体重的降低本身就是一件有利于血糖稳定控制的事。

美国糖尿病预防计划(DPP)研究小组的一项研究显示,在非盲研究7年-8年的时间里,接受二甲双胍治疗的患者,体重平均减轻3.1千克。

血管保护作用:

二甲双胍具有心血管保护作用,是目前唯一被糖尿病指南推荐为有明确心血管获益证据的降糖药物。研究表明,二甲双胍的长期治疗与新诊断的2型糖尿病患者及已经发生了心血管疾病的2型糖尿病患者的心血管疾病发生风险下降显着相关。

改善多囊卵巢综合征

多囊卵巢综合征是一种以高雄激素血症、卵巢功能障碍、多囊卵巢形态为特征的异质性疾病,其发病机制不清,患者常存在不同程度的高胰岛素血症。研究表明,二甲双胍可通过减轻胰岛素抵抗,恢复其排卵功能,改善高雄激素血症。

抗癌、抑制肿瘤作用:

近年来,多项流行病学资料显示,二甲双胍还具有预防肿瘤,甚至治疗肿瘤的作用。

肺癌是严重危害人类健康的疾病,其发病率高,病死率高,预后极差,86%的患者在确诊后5年内死亡。越来越多研究提示,二甲双胍可预防肺癌,改善肺癌患者预后。

改善肠道菌群:

有研究显示,二甲双胍能够恢复肠道菌群的比例,使其向有利于健康的方向转变。为肠道有益菌提供优势生存环境,从而起到降低血糖、正向调节免疫系统的作用。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=803608, encodeId=f7da80360873, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>两大神药之一💊, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jul 21 00:34:36 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006012, encodeId=1b9220060124d, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Sep 08 11:12:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270173, encodeId=42952e01733f, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 17 21:43:36 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269143, encodeId=ccb2269143c7, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Dec 13 15:03:07 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268911, encodeId=eaab2689111d, content=神一般的宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Tue Dec 12 20:38:33 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268887, encodeId=1c3c26888ec3, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Dec 12 17:35:10 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268701, encodeId=3607268e015d, content=真是学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Dec 11 21:56:40 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2020-07-21 lovetcm

    #阿司匹林#两大神药之一💊

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=803608, encodeId=f7da80360873, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>两大神药之一💊, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jul 21 00:34:36 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006012, encodeId=1b9220060124d, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Sep 08 11:12:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270173, encodeId=42952e01733f, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 17 21:43:36 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269143, encodeId=ccb2269143c7, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Dec 13 15:03:07 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268911, encodeId=eaab2689111d, content=神一般的宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Tue Dec 12 20:38:33 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268887, encodeId=1c3c26888ec3, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Dec 12 17:35:10 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268701, encodeId=3607268e015d, content=真是学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Dec 11 21:56:40 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=803608, encodeId=f7da80360873, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>两大神药之一💊, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jul 21 00:34:36 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006012, encodeId=1b9220060124d, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Sep 08 11:12:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270173, encodeId=42952e01733f, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 17 21:43:36 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269143, encodeId=ccb2269143c7, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Dec 13 15:03:07 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268911, encodeId=eaab2689111d, content=神一般的宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Tue Dec 12 20:38:33 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268887, encodeId=1c3c26888ec3, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Dec 12 17:35:10 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268701, encodeId=3607268e015d, content=真是学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Dec 11 21:56:40 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-17 杨柳青青

    签到学习了--

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=803608, encodeId=f7da80360873, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>两大神药之一💊, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jul 21 00:34:36 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006012, encodeId=1b9220060124d, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Sep 08 11:12:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270173, encodeId=42952e01733f, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 17 21:43:36 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269143, encodeId=ccb2269143c7, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Dec 13 15:03:07 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268911, encodeId=eaab2689111d, content=神一般的宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Tue Dec 12 20:38:33 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268887, encodeId=1c3c26888ec3, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Dec 12 17:35:10 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268701, encodeId=3607268e015d, content=真是学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Dec 11 21:56:40 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-13 杨柳青青

    签到学习了--

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=803608, encodeId=f7da80360873, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>两大神药之一💊, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jul 21 00:34:36 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006012, encodeId=1b9220060124d, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Sep 08 11:12:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270173, encodeId=42952e01733f, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 17 21:43:36 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269143, encodeId=ccb2269143c7, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Dec 13 15:03:07 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268911, encodeId=eaab2689111d, content=神一般的宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Tue Dec 12 20:38:33 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268887, encodeId=1c3c26888ec3, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Dec 12 17:35:10 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268701, encodeId=3607268e015d, content=真是学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Dec 11 21:56:40 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-12 cscs

    神一般的宣传

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=803608, encodeId=f7da80360873, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>两大神药之一💊, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jul 21 00:34:36 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006012, encodeId=1b9220060124d, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Sep 08 11:12:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270173, encodeId=42952e01733f, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 17 21:43:36 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269143, encodeId=ccb2269143c7, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Dec 13 15:03:07 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268911, encodeId=eaab2689111d, content=神一般的宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Tue Dec 12 20:38:33 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268887, encodeId=1c3c26888ec3, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Dec 12 17:35:10 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268701, encodeId=3607268e015d, content=真是学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Dec 11 21:56:40 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-12 杨柳青青

    签到学习了--

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=803608, encodeId=f7da80360873, content=<a href='/topic/show?id=51639e734cb' target=_blank style='color:#2F92EE;'>#阿司匹林#</a>两大神药之一💊, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97734, encryptionId=51639e734cb, topicName=阿司匹林)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Tue Jul 21 00:34:36 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006012, encodeId=1b9220060124d, content=<a href='/topic/show?id=68d629292b6' target=_blank style='color:#2F92EE;'>#全世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29292, encryptionId=68d629292b6, topicName=全世界)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKnILSXam1GxPwj04ylEzibYLFA2eGl5Ev02klt80JA0xejMPqrn0mYHNNnLEgyqYTPbicXpY3tn6SA/132, createdBy=38fd2500059, createdName=新生儿张玉军, createdTime=Sat Sep 08 11:12:00 CST 2018, time=2018-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=270173, encodeId=42952e01733f, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 17 21:43:36 CST 2017, time=2017-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=269143, encodeId=ccb2269143c7, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Dec 13 15:03:07 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268911, encodeId=eaab2689111d, content=神一般的宣传, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Tue Dec 12 20:38:33 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268887, encodeId=1c3c26888ec3, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Dec 12 17:35:10 CST 2017, time=2017-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=268701, encodeId=3607268e015d, content=真是学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Dec 11 21:56:40 CST 2017, time=2017-12-11, status=1, ipAttribution=)]
    2017-12-11 杨柳青青

    真是学习了--

    0

相关资讯

BMJ:低剂量阿司匹林作为下肢静脉性溃疡辅助治疗靠谱吗?

由此可见,该研究的结果并不支持使用低剂量阿司匹林作为下肢静脉溃疡的辅助治疗。

Crit Care Med:脓毒血症患者发病前服用阿司匹林竟能降低死亡风险!

2017年11月,发表在《Crit Care Med》上的一项Meta分析,研究了住院患者脓毒血症发病前乙酸水杨酸(阿司匹林)的使用对脓毒血症相关死亡的影响。研究结果证实:脓毒血症发病前服用阿司匹林的患者死亡风险降低范围是2%-12%,并且低剂量阿司匹林可作为脓毒血症患者一个降低死亡率的策略。

Clin Cancer Res:神药阿司匹林又一令人惊叹的神奇之用!

新研究显示,将阿司匹林添加到一些现有的抗癌药物中,可以提高其对抗治疗肿瘤的效力。

Neurology:低剂量阿司匹林不增加颅内出血风险,反而降低SAH风险

低剂量阿司匹林广泛应用于缺血性血管事件的二级预防,甚至用于一级预防。随机对照试验或随机对照试验联合队列研究的meta分析把阿司匹林和颅内出血风险增加联系起来,发现二者未达到统计学意义或处于边缘状态。观察性研究的结果更是模棱两可,甚至有研究认为长期服用阿司匹林能够降低蛛网膜出血的风险。

Gastroenterology:阿司匹林不能降低一般人群的胰腺癌风险

研究认为,规律的使用阿司匹林以及其他非甾体抗炎药不能降低一般人群的胰腺癌风险,仅糖尿病患者可能从阿司匹林预防中获益,但该结果需要进一步研究确证

Gastroenterology:低剂量阿司匹林不能降低食管癌或胃癌患者死亡风险

研究认为低剂量的阿司匹林不能降低食管癌或胃癌患者的死亡风险

Baidu
map
Baidu
map
Baidu
map